18 F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies
Sara Sheikhbahaei, Krystyna M. Jones, Rudolf A. Werner, Roberto A. Salas-Fragomeni, Charles V. Marcus, Takahiro Higuchi, Steven P. Rowe, Lilja B. Solnes, Mehrbod S. Javadi
Purpose: This meta-analysis aims to establish the diagnostic performance of 18 F-NaF-PET/CT for the detection of bone metastases in prostate cancer patients. The performance of 18 F-NaF-PET/CT was compared with other imaging techniques in the same cohort of patients. Methods: A systematic search was performed in PubMed/Medline and EMBASE (last Updated, September 28, 2018). Studies with histopathology confirmation and/or clinical/imaging follow-up as reference standard were eligible for inclusion. Results: A total of 14 studies were included. Twelve studies including 507 patients provided per-patient basis information. The pooled sensitivity, specificity, diagnostic odds ratio (DOR) and the area under the summary receiver operating characteristics curve (AUC) of 18 F-NaF-PET/CT for the detection of bone metastases were 0.98 (95% CI 0.95–0.99), 0.90 (95% CI 0.86–0.93), 123.2 and 0.97, respectively. Seven studies provided the lesion-based accuracy information of 1812 lesions identified on 18 F-NaF-PET/CT with the pooled sensitivity, specificity, DOR and AUC of 0.97 (95% CI 0.95–0.98), 0.84 (95% CI 0.81–0.87), 206.8 and 0.97, respectively. The overall diagnostic performance of 18 F-NaF-PET/CT is superior to 99m Tc-bone scintigraphy (AUC 0.842; P < 0.001; four studies) and 99m Tc-SPECT (AUC 0.896; P < 0.001, four studies). Compared to 18 F NaF-PET/CT, whole-body MRI with diffusion-weighted imaging (DWI) was shown to have lower sensitivity (0.83, 95% CI 0.68–0.93), with no significant difference in the overall performance (AUC 0.947; P = 0.18, four studies). Conclusion: 18 F-NaF-PET/CT has excellent diagnostic performance in the detection of bone metastases in staging and restaging of high-risk prostate cancer patients. The performance of 18 F-NaF-PET/CT is superior to 99m Tc bone scintigraphy and SPECT, and comparable to DWI–MRI.
Annals of nuclear medicine
Bone metastases
F-NaF-PET/CT
Dive into the research topics of '18 F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies'. Together they form a unique fingerprint.
Area Under Curve Medicine & Life Sciences 100%
Prostatic Neoplasms Medicine & Life Sciences 97%
Neoplasm Metastasis Medicine & Life Sciences 75%
Radionuclide Imaging Medicine & Life Sciences 47%
Sensitivity and Specificity Medicine & Life Sciences 36%
Sheikhbahaei, S., Jones, K. M., Werner, R. A., Salas-Fragomeni, R. A., Marcus, C. V., Higuchi, T., Rowe, S. P., Solnes, L. B., & Javadi, M. S. (Accepted/In press). 18 F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies. Annals of nuclear medicine. https://doi.org/10.1007/s12149-019-01343-y
18 F-NaF-PET/CT for the detection of bone metastasis in prostate cancer : a meta-analysis of diagnostic accuracy studies. / Sheikhbahaei, Sara; Jones, Krystyna M.; Werner, Rudolf A. et al.
In: Annals of nuclear medicine, 2019.
Sheikhbahaei, S, Jones, KM, Werner, RA, Salas-Fragomeni, RA, Marcus, CV, Higuchi, T, Rowe, SP, Solnes, LB & Javadi, MS 2019, '18 F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies', Annals of nuclear medicine. https://doi.org/10.1007/s12149-019-01343-y
Sheikhbahaei S, Jones KM, Werner RA, Salas-Fragomeni RA, Marcus CV, Higuchi T et al. 18 F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies. Annals of nuclear medicine. 2019. doi: 10.1007/s12149-019-01343-y
Sheikhbahaei, Sara ; Jones, Krystyna M. ; Werner, Rudolf A. et al. / 18 F-NaF-PET/CT for the detection of bone metastasis in prostate cancer : a meta-analysis of diagnostic accuracy studies. In: Annals of nuclear medicine. 2019.
@article{608a62c8b21a4ff4a9c60259b06d927b,
title = "18 F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies",
abstract = " Purpose: This meta-analysis aims to establish the diagnostic performance of 18 F-NaF-PET/CT for the detection of bone metastases in prostate cancer patients. The performance of 18 F-NaF-PET/CT was compared with other imaging techniques in the same cohort of patients. Methods: A systematic search was performed in PubMed/Medline and EMBASE (last Updated, September 28, 2018). Studies with histopathology confirmation and/or clinical/imaging follow-up as reference standard were eligible for inclusion. Results: A total of 14 studies were included. Twelve studies including 507 patients provided per-patient basis information. The pooled sensitivity, specificity, diagnostic odds ratio (DOR) and the area under the summary receiver operating characteristics curve (AUC) of 18 F-NaF-PET/CT for the detection of bone metastases were 0.98 (95% CI 0.95–0.99), 0.90 (95% CI 0.86–0.93), 123.2 and 0.97, respectively. Seven studies provided the lesion-based accuracy information of 1812 lesions identified on 18 F-NaF-PET/CT with the pooled sensitivity, specificity, DOR and AUC of 0.97 (95% CI 0.95–0.98), 0.84 (95% CI 0.81–0.87), 206.8 and 0.97, respectively. The overall diagnostic performance of 18 F-NaF-PET/CT is superior to 99m Tc-bone scintigraphy (AUC 0.842; P < 0.001; four studies) and 99m Tc-SPECT (AUC 0.896; P < 0.001, four studies). Compared to 18 F NaF-PET/CT, whole-body MRI with diffusion-weighted imaging (DWI) was shown to have lower sensitivity (0.83, 95% CI 0.68–0.93), with no significant difference in the overall performance (AUC 0.947; P = 0.18, four studies). Conclusion: 18 F-NaF-PET/CT has excellent diagnostic performance in the detection of bone metastases in staging and restaging of high-risk prostate cancer patients. The performance of 18 F-NaF-PET/CT is superior to 99m Tc bone scintigraphy and SPECT, and comparable to DWI–MRI. ",
keywords = "Bone metastases, F-NaF-PET/CT, Prostate cancer",
author = "Sara Sheikhbahaei and Jones, {Krystyna M.} and Werner, {Rudolf A.} and Salas-Fragomeni, {Roberto A.} and Marcus, {Charles V.} and Takahiro Higuchi and Rowe, {Steven P.} and Solnes, {Lilja B.} and Javadi, {Mehrbod S.}",
note = "Publisher Copyright: {\textcopyright} 2019, The Japanese Society of Nuclear Medicine. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",
doi = "10.1007/s12149-019-01343-y",
journal = "Annals of Nuclear Medicine",
publisher = "Springer Japan",
T1 - 18 F-NaF-PET/CT for the detection of bone metastasis in prostate cancer
T2 - a meta-analysis of diagnostic accuracy studies
AU - Sheikhbahaei, Sara
AU - Jones, Krystyna M.
AU - Werner, Rudolf A.
AU - Salas-Fragomeni, Roberto A.
AU - Marcus, Charles V.
AU - Higuchi, Takahiro
AU - Rowe, Steven P.
AU - Solnes, Lilja B.
AU - Javadi, Mehrbod S.
N1 - Publisher Copyright: © 2019, The Japanese Society of Nuclear Medicine. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.
N2 - Purpose: This meta-analysis aims to establish the diagnostic performance of 18 F-NaF-PET/CT for the detection of bone metastases in prostate cancer patients. The performance of 18 F-NaF-PET/CT was compared with other imaging techniques in the same cohort of patients. Methods: A systematic search was performed in PubMed/Medline and EMBASE (last Updated, September 28, 2018). Studies with histopathology confirmation and/or clinical/imaging follow-up as reference standard were eligible for inclusion. Results: A total of 14 studies were included. Twelve studies including 507 patients provided per-patient basis information. The pooled sensitivity, specificity, diagnostic odds ratio (DOR) and the area under the summary receiver operating characteristics curve (AUC) of 18 F-NaF-PET/CT for the detection of bone metastases were 0.98 (95% CI 0.95–0.99), 0.90 (95% CI 0.86–0.93), 123.2 and 0.97, respectively. Seven studies provided the lesion-based accuracy information of 1812 lesions identified on 18 F-NaF-PET/CT with the pooled sensitivity, specificity, DOR and AUC of 0.97 (95% CI 0.95–0.98), 0.84 (95% CI 0.81–0.87), 206.8 and 0.97, respectively. The overall diagnostic performance of 18 F-NaF-PET/CT is superior to 99m Tc-bone scintigraphy (AUC 0.842; P < 0.001; four studies) and 99m Tc-SPECT (AUC 0.896; P < 0.001, four studies). Compared to 18 F NaF-PET/CT, whole-body MRI with diffusion-weighted imaging (DWI) was shown to have lower sensitivity (0.83, 95% CI 0.68–0.93), with no significant difference in the overall performance (AUC 0.947; P = 0.18, four studies). Conclusion: 18 F-NaF-PET/CT has excellent diagnostic performance in the detection of bone metastases in staging and restaging of high-risk prostate cancer patients. The performance of 18 F-NaF-PET/CT is superior to 99m Tc bone scintigraphy and SPECT, and comparable to DWI–MRI.
AB - Purpose: This meta-analysis aims to establish the diagnostic performance of 18 F-NaF-PET/CT for the detection of bone metastases in prostate cancer patients. The performance of 18 F-NaF-PET/CT was compared with other imaging techniques in the same cohort of patients. Methods: A systematic search was performed in PubMed/Medline and EMBASE (last Updated, September 28, 2018). Studies with histopathology confirmation and/or clinical/imaging follow-up as reference standard were eligible for inclusion. Results: A total of 14 studies were included. Twelve studies including 507 patients provided per-patient basis information. The pooled sensitivity, specificity, diagnostic odds ratio (DOR) and the area under the summary receiver operating characteristics curve (AUC) of 18 F-NaF-PET/CT for the detection of bone metastases were 0.98 (95% CI 0.95–0.99), 0.90 (95% CI 0.86–0.93), 123.2 and 0.97, respectively. Seven studies provided the lesion-based accuracy information of 1812 lesions identified on 18 F-NaF-PET/CT with the pooled sensitivity, specificity, DOR and AUC of 0.97 (95% CI 0.95–0.98), 0.84 (95% CI 0.81–0.87), 206.8 and 0.97, respectively. The overall diagnostic performance of 18 F-NaF-PET/CT is superior to 99m Tc-bone scintigraphy (AUC 0.842; P < 0.001; four studies) and 99m Tc-SPECT (AUC 0.896; P < 0.001, four studies). Compared to 18 F NaF-PET/CT, whole-body MRI with diffusion-weighted imaging (DWI) was shown to have lower sensitivity (0.83, 95% CI 0.68–0.93), with no significant difference in the overall performance (AUC 0.947; P = 0.18, four studies). Conclusion: 18 F-NaF-PET/CT has excellent diagnostic performance in the detection of bone metastases in staging and restaging of high-risk prostate cancer patients. The performance of 18 F-NaF-PET/CT is superior to 99m Tc bone scintigraphy and SPECT, and comparable to DWI–MRI.
KW - Bone metastases
KW - F-NaF-PET/CT
KW - Prostate cancer
U2 - 10.1007/s12149-019-01343-y
DO - 10.1007/s12149-019-01343-y
JO - Annals of Nuclear Medicine
JF - Annals of Nuclear Medicine